Burgard C, Muenzenberg MD, Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F (2025)
Publication Type: Journal article
Publication year: 2025
Book Volume: 69
Pages Range: 137-145
Journal Issue: 2
DOI: 10.23736/S1824-4785.25.03627-1
BACKGROUND: This study aims to further strengthen the evidence of tumor sink effect (TSE) and to confirm this phenomenon in patients undergoing 225Ac/177Lu-PSMA tandem radioligand therapy. METHODS: The study included a total of N.=31 mCRPC patients who undergone two cycles of [177Lu]Lu-PSMA-617 RLT, with at least one cycle being augmented by [225Ac]Ac-PSMA-617. For pre- and post-therapeutic [68Ga]Ga-PSMA-11 PET/CT scans the standardized uptake value (SUV
APA:
Burgard, C., Muenzenberg, M.D., Blickle, A., Bartholomä, M., Maus, S., Petto, S.,... Rosar, F. (2025). Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 69(2), 137-145. https://doi.org/10.23736/S1824-4785.25.03627-1
MLA:
Burgard, Caroline, et al. "Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy." Quarterly Journal of Nuclear Medicine and Molecular Imaging 69.2 (2025): 137-145.
BibTeX: Download